Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
Net Income (Common)
Zealand Pharma A/S
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Zealand Pharma A/S
CSE:ZEAL
|
Net Income (Common)
-kr703.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-14%
|
|
Genmab A/S
CSE:GMAB
|
Net Income (Common)
kr5.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
32%
|
CAGR 10-Years
44%
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Net Income (Common)
-€501.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Net Income (Common)
kr984.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Bioporto A/S
CSE:BIOPOR
|
Net Income (Common)
-kr53.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-10%
|
|
Saniona AB
STO:SANION
|
Net Income (Common)
-kr95.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
See Also
What is Zealand Pharma A/S's Net Income (Common)?
Net Income (Common)
-703.7m
DKK
Based on the financial report for Dec 31, 2023, Zealand Pharma A/S's Net Income (Common) amounts to -703.7m DKK.
What is Zealand Pharma A/S's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-14%
Over the last year, the Net Income (Common) growth was 41%. The average annual Net Income (Common) growth rates for Zealand Pharma A/S have been 6% over the past three years , and -14% over the past ten years .